Search
Cyclophosphamide Treatment Options
A collection of 2172 research studies where Cyclophosphamide is the interventional treatment. These studies are located in the United States. Cyclophosphamide is used for conditions such as Breast Cancer, Lymphoma and Leukemia.
1369 - 1380 of 2172
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer
Completed
Background:
- T-cells are white blood cells that can find and kill germs and tumors. Cancer can keep T-cells from working. Researchers think a new drug called AMP-224 might help the T-cells in people with cancer. They think the drug might work even better when combined with a certain type of radiation therapy.
Objective:
- To study the safety and effectiveness of AMP-224 together with 1 or 3 days of stereotactic body radiation therapy (SBRT) directed to the liver.
Eligibility:
- People age... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
02/12/2019
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Terminated
This is a Phase 2 study to evaluate the combination of denintuzumab mafodotin in combination with RCHOP or RCHP compared with RCHOP alone as front-line therapy in patients with diffuse large B-cell lymphoma or follicular lymphoma Grade 3b.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2019
Locations: University of Alabama at Birmingham, Birmingham, Alabama +34 locations
Conditions: Diffuse, Large B-Cell, Lymphoma, Follicular Lymphoma, Grade 3b, Transformed Lymphoma / DLBCL
Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma
Completed
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells either by killing the cells or by stopping them from dividing. Vaccines made from another person's cancer cells may help the body build an effect... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
02/07/2019
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Lymphoma
RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia
Completed
The goal of Phase I of this clinical research study is to find the highest tolerable dose of RAD001 (everolimus) when given in combination with the standard chemotherapy regimens to patients with ALL.
The goal of Phase II of this study is to learn if the drug combinations can help to control ALL. The safety of these drug combinations will be also studied in both phases.
Gender:
ALL
Ages:
10 years and above
Trial Updated:
02/05/2019
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Leukemia, Acute Lymphocytic Leukemia
Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bone marrow transplantation and peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy and kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy with carboplatin and cyclophosphamide followed by bone marrow and peripheral stem cell transplantation in treating patients who have advanced ovarian... Read More
Gender:
FEMALE
Ages:
Between 18 years and 65 years
Trial Updated:
02/04/2019
Locations: Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland +1 locations
Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors
Completed
RATIONALE: Drugs used in chemotherapy, such as vinblastine, work in different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the growth of Ewing's sarcoma by stopping blood flow to the tumor. Combining more than one chemotherapy drug with celecoxib may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining low-dose vinblastine and celecoxib with standard regimens of combination chemotherapy in treating patients who have new... Read More
Gender:
ALL
Ages:
50 years and below
Trial Updated:
01/29/2019
Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +100 locations
Conditions: Sarcoma
Trial of Partial Breast Irradiation With Various Concurrent Chemotherapy Regimens
Completed
Breast conserving therapy, (BCT), which consists of wide local excision of the tumor followed by 6 weeks of whole breast irradiation, (WBI), is integral to the management of breast cancer. Evidence now suggests that WBI may not be necessary and treatment to the involved area only, partial breast irradiation, (PBI), may suffice. PBI can be achieved by interstitial or intracavitary brachytherapy, intra-op, or post op external beam radiation therapy. The feasibility, toxicity and efficacy of PBI ar... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/17/2019
Locations: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Breast Cancer
Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
Completed
OBJECTIVES: I. Confirm the efficacy demonstrated in a pilot study using high dose cyclophosphamide in patients with severe aplastic anemia.
II. Determine whether the addition of filgrastim (G-CSF) to high dose cyclophosphamide shortens the time to recovery in these patients.
III. Determine whether this regimen is efficacious in treating paroxysmal nocturnal hemoglobinuria.
Gender:
ALL
Ages:
70 years and below
Trial Updated:
01/16/2019
Locations: Johns Hopkins Oncology Center, Baltimore, Maryland
Conditions: Aplastic Anemia, Paroxysmal Hemoglobinuria, Nocturnal
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
Terminated
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Cryoablation kills cancer cells by freezing them. Giving chemotherapy together with cryoablation may kill more cancer cells.
PURPOSE: This clinical trial is studying how well giving cyclophosphamide together with cryoablation works in treating patients with advanced or metastatic epithelial cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
01/16/2019
Locations: Brady Urological Institute at Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Cancer
Preoperative Herceptin and Navelbine for Breast Cancer
Completed
The purpose of this study is to find out what effects the preoperative combination therapy of herceptin and navelbine have on HER-2 positive breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/11/2019
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Cyclophosphamide and Alemtuzumab In Lymphoma
Terminated
This research study is studying a combination of chemotherapy drugs as a possible treatment for aggressive lymphoma that has not responded to standard treatment.
The names of the study interventions involved in this study are:
* Cyclophosphamide
* Alemtuzumab
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/10/2019
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Non Hodgkin Lymphoma, High-grade B-cell Lymphoma, Diffuse Large B Cell Lymphoma
Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma
Completed
Funding Source - FDA OOPD FDR004128
The goal of this study is to see if it is safe and feasible to give chemotherapy, natural killer (NK) cells, and an antibody called 3F8. The NK cells must come from a family member who shares half of the HLA proteins which are immune proteins important in transplant. NK cells are a type of white blood cell. They can recognize and kill abnormal cells in the body and can work together with antibodies to kill target cells. The antibody 3F8 specifically recognize... Read More
Gender:
ALL
Ages:
All
Trial Updated:
01/09/2019
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Neuroblastoma, Bone Marrow, Sympathetic Nervous System
1369 - 1380 of 2172